Next-generation prostate-specific antigen test: Ready to use?

European Urology

Volumn 64, Issue 5, 2013, Pages 700-702

  Bjartell, Anders S ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; KALLIKREIN RELATED PEPTIDASE 2; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE; UNCLASSIFIED DRUG;

BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SIZE; CLINICAL PRACTICE; DIAGNOSTIC TEST; EDITORIAL; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; PROSTATECTOMY; URINALYSIS; VALIDATION STUDY;

DECISION SUPPORT TECHNIQUES; HUMANS; KALLIKREINS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TISSUE KALLIKREINS;

EID: 84885421416     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.06.052     Document Type: Editorial

References (10)

1. A.W. Roddam, M.J. Duffy, and F.C. Hamdy Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis Eur Urol 48 2005 386 399
2. S. Carlsson, A. Maschino, and F. Schröder Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer Section Rotterdam Eur Urol 64 2013 693 699
3. J.I. Epstein, D.W. Chan, and L.J. Sokoll Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings J Urol 160 1998 2407 2411
4. E.W. Steyerberg, M.J. Roobol, and M.W. Kattan Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram J Urol 177 2007 107 112
5. E.K. Vos, G.J.S. Litjens, and T. Kobus Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T Eur Urol 64 2013 448 455
6. S. Loeb, L.J. Sokoll, and D.L. Broyles Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration J Urol 189 2013 1702 1706
7. G. Guazzoni, M. Lazzeri, and L. Nava Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer Eur Urol 61 2012 455 466
8. A.J. Vickers, and H. Lilja PSA is dead, long live PSA Eur Urol 61 2012 467 478
9. Leyten GHJM, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. In press. http://dx.doi.org/ 10.1016/j.eururo.2012.11.014
10. V. Scattoni, M. Lazzeri, and G. Lughezzani Head-to-head comparison of Prostate Health Index and urinary PCA3 for predicting the presence of cancer at initial or repeat biopsy J Urol 190 2013 496 501